Varicella Attenuated Live Vaccine Market Size, Share, Growth, Trends and Industry Analysis, By Type (Monovalent Vaccine, Combination Vaccine), By Application (Kids Injection, Adults Injection), Regional Insights and Forecast From 2025 to 2033

• 

  Request a Free sample to learn more about this report

VARICELLA ATTENUATED LIVE VACCINE MARKET REPORT OVERVIEW

The global varicella attenuated live vaccine market size was estimated at USD 2.91 billion in 2024, set to expand to USD 4.25 billion by 2033, growing at a CAGR of 4.3% during the forecast period from 2025 to 2033.

Varicella zoster, also known as human alphaherpesvirus 3, causes zoster and chicken pox in humans. Infection with this virus can be prevented using vaccinations specially designed to provide immunity against the virus. These vaccines differ from each other in terms of content. For example, the monovalent varicella vaccine contains only one strain of the virus, while the combined varicella vaccine contains more than one strain of the virus and provides immunity against more than one virus. Vaccination is the administration of antigenic components that stimulate protective immunity against a specific infectious disease.

The demand for vaccines has increased due to the high incidence of global diseases. For example, the Saudi Ministry of Health recommended influenza vaccination for all Hajj pilgrims, especially tourists with chronic diseases. These vaccines are mandatory for all health workers working in Mecca and Medina Hajj pilgrimage centers. According to the WHO, viral hepatitis affects 325 million people, or about 4 percent of the world's population, and the disease causes 1.34 million deaths each year. The new research study consists of an industry trend analysis of the market. Growing government support and focus for development of vaccine & immunization, and increasing prevalence of infectious diseases, are driving the market.

COVID-19 IMPACT

Pandemic Leads To Shifting Of Market To COVID Vaccines Leading Decline In Market Growth

The COVID-19 pandemic has been unprecedented and staggering, with the varicella attenuated live vaccine market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden rise in CAGR is attributable to the market’s growth and demand returning to pre-pandemic levels.

The coronavirus was discovered at the end of December in the city of Wuhan, Hubei province, China. The disease is caused by a virus, namely severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is transmitted from person to person. After the disease was discovered in Wuhan, the disease quickly spread to other parts of the world. This virus causes various symptoms in the patient; common symptoms include fever, dry cough and fatigue. However, serious symptoms include difficulty breathing or shortness of breath, chest pain or pressure, and loss of speech or movement. The overall impact of COVID-19 on the varicella attenuated live vaccine market remains negative as the market focus has shifted from traditional vaccines to COVID-19 vaccines. Along with this, the pandemic has affected the supply chain, causing lower demand and higher inventory adjustments. In addition, major vaccine manufacturers focused mainly on the production of COVID-19 and abandoned parts of their vaccines due to the large R&D investment in COVID-19 vaccines.

LATEST TRENDS

Monovalent Varicella Vaccine Segment Is Expected To Hold A Significant Market Share In The Vaccine Market Growth

The monovalent varicella vaccine segment holds a significant market share in the varicella vaccine market and is expected to show a similar trend during the forecast period as these vaccines have less potential to cause febrile seizures in children as compared to combination vaccines. Monovalent vaccines contain one strain of the live varicella vaccine, containing a weakened strain of the varicella virus.

Request a Free sample to learn more about this report

VARICELLA ATTENUATED LIVE VACCINE MARKET SEGMENTATION

By Type

According to type, the market can be segmented into Monovalent Vaccine, Combination Vaccine. Monovalent Vaccine is anticipated to be the leading segment.

By Application

Based on application, the market can be divided into Kids Injection, Adults Injection.

Kids Injection will be the dominating segment.

DRIVING FACTORS

Rising Cases Of New And Recurring Infectious Diseases to Fuel The Market Growth

As people come into closer contact with wild animals, travel more often and longer distances than before, and live in more densely populated areas, there is great concern about the rapid spread of new infectious diseases  and the creation of global epidemics. In addition, there is the possibility that diseases may arise if they are introduced into animal, human or plant populations intentionally for terrorist purposes. About 40 infectious diseases have been discovered, including SARS, MERS, Ebola, chikungunya, bird flu, swine flu, Zika, and most recently, COVID-19. Experts have warned of future pandemics and even deadlier pandemics than COVID-19. The frequency of these infectious diseases ensures that the demand for vaccines will continue and grow in the coming years. Thus, factors such as emergence of new diseases will ensure better R and D funding initiatives, strong pipeline and new vaccine options for large population groups and drive the market growth.

Increasing Vaccination Programs And Advances In Vaccine Technology to Boost The Market Growth

Increasing vaccination programs across the globe is a major factor stimulating the growth of the market. Additionally, increasing awareness about the use of live varicella vaccines and increasing popularity of live varicella vaccines across the world are also fueling the growth of the live varicella vaccine market. However, the growth of the market is limited by the large financial investments related to the manufacture of the products. On the other hand, the growth potential of developing economies creates profitable opportunities for the market during the forecast period. Additionally, advances in vaccine technology provide an opportunity to target new diseases that support market growth. A wide variety of new vaccination methods have been developed, from targeted attenuation techniques of live pathogens to  delivery of bioengineered protein and peptide antigens, as well as viral vectors and nucleic acid-based antigens. Most of these technologies have very promising results. As a result, significant investments have been made in the development of vaccine technology, which promotes market growth.

RESTRAINING FACTOR

Longer Timeline For Vaccine Production And High Cost Of Vaccine Development Is to Restrain The Market Growth 

Determining the efficacy, quality and safety of a new vaccine is a huge process that usually takes about 10 to 15 years. Complexity of clinical development, vaccine research and legislative requirements are the three main reasons for long deadlines. There are significant regional differences in regulation in different parts of the world within clinical trials. This can therefore cause significant delays in the development of new vaccines. Limited vaccine coverage and unreasonable transport and storage costs of vaccines will have some negative impact on the expansion of the industry in the near future. In addition, strict government product approval regulations are expected to increase time to market for new products; thus limiting the growth of the vaccine market. Developing vaccines is a huge capital-intensive operation. The cost of storing and distributing vaccines is higher than any other pharmaceutical product because it requires tracking equipment and specialized equipment. Lack of adequate storage and distribution facilities can reduce vaccine effectiveness efficiency and quality. The development process (from in vitro studies to commercialization) takes 10-15 years and requires an investment of 800-1 billion dollars. In addition, manufacturers find it difficult to manage operating costs and increase initial investment due to the low success rate of vaccine development. Consequently, the high cost of developing and maintaining vaccines is restraining the market growth.

• Request a Free sample to learn more about this report

•  

VARICELLA ATTENUATED LIVE VACCINE MARKET REGIONAL INSIGHTS

North America To Dominate The Market Due To Easy Availability Of Live Vaccines

North America accounted for the largest varicella attenuated live vaccine market share in 2018 and this trend is expected to continue due to easy availability of live varicella vaccine, skilled healthcare professionals and key players of live varicella vaccine. Asia Pacific is expected to grow the fastest during the forecast period due to the importance of vaccination and rising disposable income. Developing economies offer lucrative opportunities for suppliers of live varicella vaccines to expand their business. The ever-evolving life sciences industry is driving varicella attenuated live vaccine market growth in emerging economies such as India, China, Malaysia and others.

KEY INDUSTRY PLAYERS

Key Players Focus on Partnerships to Gain a Competitive Advantage

Prominent market players are making collaborative efforts by partnering with other companies to stay ahead of the competition. Many companies are also investing in new product launches to expand their product portfolio. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolios.

List of Top Varicella Attenuated Live Vaccine Companies

• Merck (U.S.)
• BCHT (China)
• Shanghai Institute (China)
• GSK (U.K.)
• Keygen (Canada)
• Green Cross (South Korea)
• Biken (Japan)
• Shanghai Rongsheng Biotech (China)
• Changchun Changsheng Life Sciences Limited (China)

REPORT COVERAGE

This research profiles a report with extensive studies that take into description the firms that exist in the market affecting the forecasting period. With detailed studies done, it also offers a comprehensive analysis by inspecting the factors like segmentation, opportunities, industrial developments, trends, growth, size, share, and restraints. This analysis is subject to alteration if the key players and probable analysis of market dynamics change.